Astellas Pharma (4503) Stock Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.

4503 Stock Information

Symbol4503

Address

2-5-1, Nihonbashi-HonchoTokyo, 103-8411Japan

Founded-

Trading hours-

Websitehttps://www.astellas.com

Country🇯🇵 Japan

Phone Number81 3 3244 3000

Astellas Pharma (4503) Price Chart

Astellas Pharma Overview: Key Details and Summary

Stock data	2023	Change
Price	$10.07	N/A
Market Cap	$18.33B	N/A
Shares Outstanding	1.82B	-1.61%
Employees	14.48K	N/A
Shareholder Equity	1.51T	3.26%

Valuation	2023	Change
P/E Ratio	0.19	N/A
P/S Ratio	1.90	N/A
P/B Ratio	0.01	N/A
P/FCF	12.04	N/A

Dividends	2023	Change
Dividend Yield	3.49%	N/A
Dividend per share	0.3511	N/A
Dividend Payout Ratio	1.0166	N/A

Growth	2023	Change
ROIC	0.1099	N/A
CAPEX	-232.04M	N/A
Return on Equity	0.0004	N/A

Earnings	2023	Change
Revenue	$9.67B	N/A
Earnings	$628.57M	N/A
Free Cash Flow	$1.52B	N/A
EPS	54.09	N/A
Earnings Yield	5.37	N/A
Gross Margin	0.8101	N/A
Operating Margin	0.0866	N/A
Net income margin	0.065	N/A
FCF Margin	0.1575	N/A

Financial Strength	2023	Change
Total Assets	$15.64B	N/A
Cash on Hand	$2.53B	N/A
Debt to Equity	0.0040	5.33%
Current Ratio	$1.45	7.66%

Other data	2023	Change
Buyback Yield	0.0210	N/A